Your browser doesn't support javascript.
loading
Assessing the quality of publicly available videos on MDMA-assisted psychotherapy for PTSD.
Kyarunts, Mariam; Mansukhani, Meghna P; Loukianova, Larissa L; Kolla, Bhanu P.
Afiliación
  • Kyarunts M; Mayo Clinic Alix School of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Mansukhani MP; Department of Family Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Loukianova LL; Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota, USA.
  • Kolla BP; Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota, USA.
Am J Addict ; 31(6): 502-507, 2022 11.
Article en En | MEDLINE | ID: mdl-36000281
BACKGROUND AND OBJECTIVES: Patients increasingly rely on the Internet for healthcare information. This study aimed to evaluate the quality of videos on 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic stress disorder (PTSD) on YouTube™. METHODS: YouTube™ was searched for the terms "MDMA" and "PTSD." The 100 most viewed videos were analyzed using three standard quality measures: Global Quality Scores (GQS), JAMA benchmark, and DISCERN. Viewer engagement features and source of upload, video duration, inclusion of patient narrative and/or MD/DO/PhD, the mention of lack of Food and Drug Administration (FDA) approval, side effects, potential for abuse, and use in conjunction with psychotherapy were recorded. RESULTS: The videos were of poor quality (mean GQS: 2.26 ± 0.94/5, JAMA: 1.96 ± 0.45/4, and DISCERN: 29.5 ± 8.2/80). A significant positive association was found between video quality and duration (GQS: r = .5857, p < .0001, JAMA: r = .279, p = .0409, DISCERN: r = .5783, p < .0001). Videos including an MD/DO/PhD had the highest scores (GQS: 2.87/5 [1.22], p = .006, DISCERN: 38.35/80 [13.32], p < .0003). A minority of videos were uploaded by academic institutions (1%); most were from professional organizations (29%). No correlation was found between quality and viewer engagement features-number of views, subscribers, likes/dislikes, or comments. A majority mentioned that MDMA must be used in conjunction with psychotherapy (85%) and is not FDA-approved (82%) for PTSD. Only 32% of videos mentioned risks or potential for abuse. CONCLUSIONS: These findings highlight the need for better quality of online health material and an opportunity for involvement of healthcare professionals in the dissemination of accurate health information via content creation. SCIENTIFIC SIGNIFICANCE: This is the first study to examine publicly available information on the use of MDMA for PTSD.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trastornos por Estrés Postraumático / N-Metil-3,4-metilenodioxianfetamina / Medios de Comunicación Sociales Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: Am J Addict Asunto de la revista: TRANSTORNOS RELACIONADOS COM SUBSTANCIAS Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trastornos por Estrés Postraumático / N-Metil-3,4-metilenodioxianfetamina / Medios de Comunicación Sociales Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: Am J Addict Asunto de la revista: TRANSTORNOS RELACIONADOS COM SUBSTANCIAS Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido